Millstone Evans Group LLC Acquires Shares of 190 United Therapeutics Co. (NASDAQ:UTHR)

Millstone Evans Group LLC purchased a new position in United Therapeutics Co. (NASDAQ:UTHR) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 190 shares of the biotechnology company’s stock, valued at approximately $67,000.

Other institutional investors have also recently made changes to their positions in the company. Newbridge Financial Services Group Inc. acquired a new stake in shares of United Therapeutics in the fourth quarter worth approximately $25,000. Brooklyn Investment Group acquired a new stake in shares of United Therapeutics in the third quarter worth approximately $33,000. MassMutual Private Wealth & Trust FSB boosted its stake in shares of United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 58 shares during the last quarter. Jones Financial Companies Lllp boosted its stake in shares of United Therapeutics by 678.9% in the fourth quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company’s stock worth $104,000 after acquiring an additional 258 shares during the last quarter. Finally, SBI Securities Co. Ltd. acquired a new stake in shares of United Therapeutics in the fourth quarter worth approximately $131,000. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Stock Down 0.2 %

NASDAQ:UTHR opened at $312.99 on Monday. United Therapeutics Co. has a 52 week low of $221.53 and a 52 week high of $417.82. The company has a market capitalization of $14.06 billion, a P/E ratio of 13.75, a P/E/G ratio of 0.97 and a beta of 0.64. The stock’s fifty day moving average is $345.10 and its two-hundred day moving average is $357.05.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. During the same quarter in the previous year, the business earned $4.36 earnings per share. Sell-side analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on UTHR shares. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 27th. HC Wainwright reissued a “buy” rating and set a $425.00 price objective on shares of United Therapeutics in a research note on Thursday, February 27th. Finally, UBS Group boosted their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $388.25.

Insider Activity at United Therapeutics

In related news, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction on Monday, December 30th. The stock was sold at an average price of $356.68, for a total value of $3,566,800.00. Following the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $919,164.36. The trade was a 79.51 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Nilda Mesa sold 255 shares of the business’s stock in a transaction on Monday, December 30th. The shares were sold at an average price of $355.77, for a total value of $90,721.35. Following the completion of the sale, the director now owns 5,528 shares in the company, valued at $1,966,696.56. This represents a 4.41 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 80,255 shares of company stock worth $28,995,021. 11.90% of the stock is currently owned by company insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.